MVA 5T4

Drug Profile

MVA 5T4

Alternative Names: 5T4 cancer vaccine; Cancer vaccine - Oxford Biomedica; Modified vaccinia Ankara 5T4; MVA-5T4; MVA-h 5T4; OBA 1 cancer vaccine; OXB-301; Recombinant modified vaccinia Ankara 5T4 vaccine; rV-5T4-VAC; SAR-109659; TroVax

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Developer Cardiff University; Oxford BioMedica; University College London; Wales Cancer Trials Unit
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer; Mesothelioma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 01 Nov 2013 Oxford BioMedica initiates enrolment in a phase II TRIOC trial in Ovarian cancer (second-line therapy or greater, early-, mid-stage disease) in United Kingdom(NCT01556841)
  • 29 Jul 2013 Efficacy and adverse events data from a phase II trial in Prostate cancer (combination therapy, hormone refractory) released by Oxford BioMedica
  • 07 Mar 2013 Phase-II clinical trials in Mesothelioma (first-line, combination therapy) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top